



ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored product, event or publication. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO.

Organizers: SAKK, Founding Sponsor: AstraZeneca, Co-Sponsors: AstraZeneca, MSD, NOVARTIS, etc.

Sunday / May 31, 2020				
09:00 Introduction				
09:00 - 12:00	Gastro-Intestinal	<i>Presented by: Dr. med. Daniel Heideig, Prof. Dr. med. Ulrich Guller</i> <i>Live experts: Dr. med. Sara De Dossa, Dr. Stefanie Hayoz, Prof. Dr. med. Wolfram Jochum, PD Dr. med. Ulf Petrausch, Prof. Dr. med. Daniel R. Zwahlen, PD Dr. med. univ. Thomas Winder</i>		
Abstract no	Entity	First Author	Titel	Link to the video
4505	Upper GI	Ghaneh	ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.	https://meetinglibrary.asco.org/record/185467/video
4502	Upper GI	Hofheinz	Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.	https://meetinglibrary.asco.org/record/186001/video
4004	Lower GI	Sobrero	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration	https://meetinglibrary.asco.org/record/185483/video
4002	Lower GI	Lonardi	First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.	https://meetinglibrary.asco.org/record/185499/video
4001	Lower GI	Koepetz	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).	https://meetinglibrary.asco.org/record/185472/video
Break				
4007	Lower GI	Conroy	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.	https://meetinglibrary.asco.org/record/185485/video
4006	Lower GI	Hospers	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.	https://meetinglibrary.asco.org/record/185464/abstract
4008	Lower GI	Garcia-Aguilar	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.	https://meetinglibrary.asco.org/record/187194/video
Discussion of 4006-8	Lower GI	Leigh Hallemeier	Time to Reflect on What We Do Below the Peritoneal Reflection	https://meetinglibrary.asco.org/record/187289/video
Wrap-Up				
All: Panda, Beacon, Prodig23 and Rapido				